BioCanRx and its partners announced $2.8 million in funding for two collaborative research projects including a clinical trial aiming to treat hematologic cancers with MiHA-targeted immunotherapy.
These projects come out of the latest round of BioCanRx’s full applications.
Funding partners for these projects include Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS), Hôpital Maisonneuve-Rosemont, AmorChem – Specifit, Center of Excellence in Cell Therapy – Hôpital Maisonneuve-Rosemont, C3i, CellCan, Northern Biologics, Ontario Institute for Cancer Research and Princess Margaret Cancer Centre – University Health Network.
Dr. Robert Rottapel and Dr. Denis-Claude Roy will each lead national research teams comprised of researchers, clinicians, and trainees working together to find improved treatment options and outcomes for cancer patients. Here are the objectives of the two-funded projects:
- Rottapel’s Catalyst project aims to develop monoclonal antibodies (mAb) targeting the Relaxin hormonal pathway as a therapeutic treatment for ovarian cancer.
- Roy’s Clinical Trial aims to provide safer and more effective treatments for patients with resistant hematologic cancers (HC). They have identified 39 MiHA that are preferentially expressed on HC over other tissues, thus minimizing the risk of Graph versus host disease. They will initiate a clinical trial using this novel strategy to treat patients with lymphoid HCs and also expand the HLA typing repertoire in order to increase patient reach.
Read the full project summaries:
Call for new applications
BioCanRx also said that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs.
BioCanRx is placing the highest priority on the intake of new applications for funding, proposing research activities that would be likely to add value to, facilitate the implementation of, or enhance the translation to the clinic of, technologies within the existing BioCanRx portfolio of research investments.
The projects contained within the BioCanRx research portfolio are found here.
New applications will be expected to speak very specifically to the value-add of their proposed research deliverables and the complementarity to support the successful development of BioCanRx technologies or research projects.
Applicants should be aware that all projects must plan to be completed no later than March 31, 2020.
It is unlikely that new clinical trial projects will be funded in this next call for proposals unless the trial is of a small pilot scale and the applicant(s) can convincingly demonstrate the feasibility of completion of the study by March 31, 2020.
Next LOI submission deadline will be 11:59 am EST on November 1, 2017, invited full applications are anticipated by mid-February (date TBD) for funding to commence by April 1, 2018.